Dynavax demonstrated strong financial performance with record revenue and market share growth for HEPLISAV-B, alongside meaningful pipeline advancements and new programs. However, financial challenges such as a significant allowance for doubtful accounts and a substantial GAAP net loss due to debt refinancing impacted the quarter. Despite these challenges, the overall outlook remains positive with expectations of achieving the upper half of revenue guidance and strong EBITDA growth.

Company Guidance -

Q3 2025

In the Dynavax Technologies' First Quarter 2025 Financial Results Conference Call, the company provided guidance with several key metrics. They reported a record first quarter net revenue for HEPLISAV-B of $65 million, a 36% increase from the previous year, putting them on track to reach the top half of their annual guidance range of $305 million to $325 million in net product sales. HEPLISAV-B's U.S. market share increased to 43% in Q1 2025 from 41% the previous year, with expectations of reaching over 60% by 2030 as the market is anticipated to peak at $900 million. Additionally, they are advancing their shingles program, with a top line readout expected in Q3 2025, and have announced new programs for pandemic influenza and Lyme disease. The company is executing a $200 million share repurchase program, having completed over 85% of it, and aims to maintain disciplined cost management with SG&A expenses expected to remain flat for the year. They reaffirmed their HEPLISAV-B gross margin guidance at approximately 80% for 2025.

Record First Quarter Net Revenue for HEPLISAV-B

Dynavax reported its highest ever first quarter net revenue for HEPLISAV-B at $65 million, which was a 36% increase compared to the previous year. This performance sets the company on track to achieve the top half of their full-year guidance range of net product sales between $305 million and $325 million.

Expansion of Development Pipeline

Dynavax is advancing its development pipeline with significant clinical trial milestones for its shingles and plague vaccine programs. Additionally, new programs for pandemic influenza and Lyme disease vaccines were announced, leveraging their CpG-1018 adjuvant technology.

Strong Market Position for HEPLISAV-B

HEPLISAV-B's estimated U.S. market share rose to 43% in Q1, up from 41% in the same period last year, driven by broad-based gains and consistent annual market share increases across major retail customers.

Positive Financial Outlook

Dynavax expects adjusted EBITDA to be at least $75 million for the full year 2025, demonstrating their ability to grow adjusted EBITDA at more than two times the rate of product revenue.

Dynavax (DVAX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DVAX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.14 / -	0.12	―	―	―
Aug 07, 2025	2025 (Q2)	0.10 / 0.14	0.08	75.00% (+0.06)
May 06, 2025	2025 (Q1)	0.03 / -0.77	-0.07	-1000.00% (-0.70)
Feb 20, 2025	2024 (Q4)	0.04 / 0.05	0	―
Nov 07, 2024	2024 (Q3)	0.11 / 0.12	0.1	20.00% (+0.02)
Aug 06, 2024	2024 (Q2)	0.07 / 0.08	0.03	166.67% (+0.05)
May 08, 2024	2024 (Q1)	-0.02 / -0.07	-0.19	63.16% (+0.12)
Feb 22, 2024	2023 (Q4)	-0.01 / 0.00	0.45	―
Nov 02, 2023	2023 (Q3)	-0.04 / 0.10	0.43	-76.74% (-0.33)
Aug 03, 2023	2023 (Q2)	-0.09 / 0.03	0.87	-96.55% (-0.84)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DVAX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2025	$10.92	$9.72	-10.99%
Feb 20, 2025	$13.33	$13.33	0.00%
Nov 07, 2024	$12.02	$13.01	+8.24%
Aug 06, 2024	$10.05	$10.75	+6.97%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dynavax Technologies (DVAX) report earnings?

Dynavax Technologies (DVAX) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Dynavax Technologies (DVAX) earnings time?

Dynavax Technologies (DVAX) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DVAX EPS forecast?

DVAX EPS forecast for the fiscal quarter 2025 (Q3) is 0.15.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing